Addex Therapeutics Ltd (ADXN) Key Metrics
ADXN key metrics, 2016–2025
Fiscal year ended December 31, 2025 · Swiss francsADXN returns How much profit the business earns on the capital it uses.
ADXN financial health Debt, liquidity and how easily interest is covered.
ADXN efficiency & capital use Working capital cycle and where the cash goes.
ADXN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ADXN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ADXN cash returned to shareholders
ADXN key metrics in Swiss francs
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −93.2% | 130.4% | −348.5% | −190.5% | −97.3% | −64.1% | −45.6% | −8.1% | −420.3% | −334.5% |
| Return on invested capital (ROIC) | −46.7% | −109.0% | — | — | — | — | — | — | — | — |
| Return on assets (ROA) | −78.9% | 92.1% | −163.4% | −135.0% | −71.9% | −48.3% | −39.3% | −7.3% | −138.2% | −137.7% |
| Return on tangible assets | −105.7% | 66.1% | −227.4% | −251.2% | −68.1% | −63.7% | −196.9% | −3.9% | −107.1% | −187.1% |
| Free cash flow margin | — | — | −495.9% | — | −505.3% | −338.8% | −344.2% | 28.8% | −427.2% | — |
| Income quality (OCF / net income) | — | −0.76 | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | CHF 34,727 | CHF 41,994 | CHF 344,336 | CHF 373,135 | CHF 482,014 | CHF 567,396 | CHF 550,245 | CHF 14,921 | CHF 10,979 | — |
| Cash & short-term investments | CHF 1.6M | CHF 3.3M | CHF 3.9M | CHF 7.0M | CHF 20.5M | CHF 18.8M | CHF 31.6M | CHF 41.7M | CHF 2.6M | CHF 1.4M |
| Net debt | −CHF 1.6M | −CHF 3.3M | −CHF 3.5M | −CHF 6.6M | −CHF 20.0M | −CHF 18.2M | −CHF 31.0M | −CHF 41.7M | −CHF 2.6M | −CHF 1.4M |
| Debt / equity | 0.01 | 0.00 | 0.30 | 0.08 | 0.03 | 0.04 | 0.02 | 0.00 | 0.01 | — |
| Debt / assets | 0.01 | 0.00 | 0.07 | 0.05 | 0.02 | 0.03 | 0.02 | 0.00 | 0.00 | — |
| Current ratio | 1.40 | 4.42 | 1.46 | 2.39 | 5.31 | 5.38 | 5.70 | 18.06 | 2.07 | 1.33 |
| Quick ratio | 1.40 | 4.42 | 1.46 | 267.95 | 5.31 | 5.34 | 5.70 | 18.06 | 2.07 | 1.33 |
| Interest coverage | — | -776.8 | -103.8 | -215.6 | -246.1 | -176.2 | -113.6 | -6.5 | -71.3 | -452.0 |
| Working capital | CHF 476,571 | CHF 2.7M | CHF 1.3M | CHF 4.5M | CHF 17.8M | CHF 15.9M | CHF 26.7M | CHF 39.8M | CHF 1.6M | CHF 408,622 |
| Invested capital | CHF 3.2M | CHF 6.4M | −CHF 2.4M | −CHF 1.7M | −CHF 3.1M | −CHF 3.6M | −CHF 5.5M | −CHF 2.4M | −CHF 1.2M | −CHF 1.2M |
| Tangible asset value | CHF 4.8M | CHF 9.7M | CHF 1.1M | CHF 4.9M | CHF 16.9M | CHF 14.6M | CHF 0 | CHF 39.2M | CHF 1.3M | CHF 218,592 |
| Net current asset value | CHF 77,502 | CHF 2.5M | CHF 738,185 | CHF 4.5M | CHF 16.3M | CHF 13.9M | CHF 24.9M | CHF 39.2M | CHF 1.3M | CHF 194,187 |
| Capital allocation | ||||||||||
| Dividends paid | CHF 0 | CHF 0 | CHF 0 | CHF 307,496 | CHF 390,189 | CHF 0 | CHF 0 | CHF 0 | CHF 0 | CHF 0 |
| Share buybacks (net) | CHF 28,850 | CHF 25,782 | CHF 48,051 | CHF 307,496 | CHF 390,189 | — | CHF 0 | CHF 5,373 | CHF 0 | CHF 0 |
| Dividend payout ratio | — | 0.0% | — | — | — | — | — | — | — | — |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | 0.3% | — | — |
| Capex / revenue | 0.0% | 0.3% | 0.4% | 0.0% | 1.1% | 1.6% | 1.0% | 0.1% | 0.1% | 64.8% |
| Capex / operating cash flow | — | — | — | — | — | — | — | 0.5% | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.02 | 0.00 | 0.09 | 0.16 | 0.09 | 3.08 | 0.05 | 0.44 |
| Stock-based compensation / revenue | — | — | 111.3% | 258.9% | 40.4% | 32.6% | 61.0% | 38.0% | 160.1% | 1,138.8% |
| R&D / revenue | 634.6% | 107.7% | 58.4% | 554.2% | 309.1% | 287.1% | 450.8% | 39.2% | 168.3% | 4,728.1% |
| SG&A / revenue | 6,299.0% | 414.5% | 125.9% | 229.3% | 265.6% | 159.1% | 156.0% | 78.0% | 439.3% | 8,785.0% |
| Efficiency | ||||||||||
| Days sales outstanding | 216.9 | 75.3 | 84.8 | 118.4 | 24.6 | 9.4 | 25.8 | 17.4 | 191.5 | 3,715.5 |
| Days of inventory on hand | — | — | — | -10,877.6 | 2.3 | 2.6 | -22.2 | — | 0.0 | — |
| Days payables outstanding | 15,329.8 | 264.4 | 59.5 | 38.2 | 39.4 | 56.3 | 2,668.9 | 1,939.3 | 6,455.9 | 8,852.5 |
| Cash conversion cycle (days) | -15,112.9 | -189.1 | 25.3 | -10,797.4 | -12.5 | -44.3 | -2,665.2 | -1,921.9 | -6,264.3 | -5,137.0 |
| Receivables turnover | 1.68 | 4.85 | 4.30 | 3.08 | 14.85 | 38.76 | 14.13 | 20.95 | 1.91 | 0.10 |
| Payables turnover | 0.02 | 1.38 | 6.14 | 9.55 | 9.25 | 6.48 | 0.14 | 0.19 | 0.06 | 0.04 |
| Inventory turnover | — | — | — | — | 157.44 | 139.36 | — | — | 29,764.00 | — |
| Asset turnover | 0.00 | 0.05 | 0.25 | 0.09 | 0.14 | 0.14 | 0.07 | 0.27 | 0.21 | 0.01 |
| Average receivables | CHF 17,811 | CHF 83,390 | CHF 374,792 | CHF 461,368 | CHF 196,397 | CHF 93,200 | CHF 195,522 | CHF 288,449 | CHF 262,302 | CHF 176,399 |
| Average payables | CHF 428,438 | CHF 618,837 | CHF 1.1M | CHF 1.5M | CHF 1.4M | CHF 1.6M | CHF 1.7M | CHF 766,006 | CHF 526,444 | CHF 420,288 |
| Average inventory | — | — | — | −CHF 435.8M | CHF 81,420 | CHF 74,436 | −CHF 13,968 | — | CHF 1 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 77.3% | 0.0% | 0.0% | 0.0% |
Computed from ADXN's annual financial statements (latest annual report filed May 15, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in Swiss francs; data from EODHD. Averages use the opening and closing balance of each year.
ADXN valuation and financial ratios
Addex Therapeutics earned a return on equity of −93.2% and a return on invested capital of −46.7% in fiscal 2025. It ended the year with CHF 0.0 million of debt and CHF 1.6 million in cash and short-term investments, a net cash position of CHF 1.6 million. It returned CHF 0.0 million to shareholders: CHF 0 in dividends and CHF 0.0 million in share buybacks.
See the ADXN income statement, the ADXN chart for price history, or the ADXN stock overview for the latest quote and news.
ADXN key metrics FAQ
What is Addex Therapeutics's return on equity?
Addex Therapeutics's return on equity (ROE) was −93.2% in fiscal 2025: net income of -CHF 6.7 million on average shareholders' equity of CHF 7.2 million.
What is Addex Therapeutics's ROIC?
Addex Therapeutics's return on invested capital was −46.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Addex Therapeutics have?
Addex Therapeutics had total debt of CHF 0.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
Does Addex Therapeutics pay a dividend?
Addex Therapeutics did not pay a dividend in fiscal 2025.
Does Addex Therapeutics buy back its shares?
Yes. Addex Therapeutics spent CHF 0.0 million on net share repurchases in fiscal 2025.
What is Addex Therapeutics's current ratio?
Addex Therapeutics's current ratio was 1.40 at the end of fiscal 2025: current assets were 1.40 times current liabilities.